Phase 3 HIV and AIDS Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults who have been admitted to one of the hospitals taking part in this study
- People living with HIV, whether or not they are currently taking HIV medications
- People who have been diagnosed with a widespread form of a fungal infection called histoplasmosis, confirmed through laboratory or tissue testing, or through a urine antigen test
- People who have a brain or nervous system infection may be considered if doctors believe there is a different infection (not histoplasmosis) causing it
- People currently taking a medication called fluconazole for a mouth or throat yeast infection may still be considered
Who may not be able to join:
- People who do not wish to take part in the trial
- People who have previously been diagnosed with histoplasmosis
- People who are pregnant or breastfeeding
- People who have significant kidney problems, based on blood test results showing kidney function below a certain level (confirm with trial site)
- People who have had a severe reaction to a type of antifungal medication called a polyene antifungal in the past
- People who have received more than one dose of a polyene antifungal medication in the 48 hours before joining the trial
- People whose histoplasmosis is suspected to involve the brain or nervous system
- People who, in their treating doctor's opinion, may not survive beyond the next 48 hours
- People who also have a fungal infection called cryptococcus
- People who are currently being treated for, or receiving preventive treatment for, a parasitic infection called leishmaniasis using amphotericin
- People who are unable to take medication by mouth or through a feeding tube, as determined by the lead doctor at each site
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Daiane F Dalla Lana, PhD, Federal University of Health Science of Porto Alegre
Phone: +5551999951614
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Overall survival rate
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.